Daiwa Securities Group’s Theravance Biopharma TBPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-115
Closed -$2K 1420
2025
Q4
$2K Sell
115
-100
-47% -$1.66K ﹤0.01% 1325
2025
Q3
$3K Hold
215
﹤0.01% 1251
2025
Q2
$2K Hold
215
﹤0.01% 1229
2025
Q1
$2K Hold
215
﹤0.01% 1198
2024
Q4
$2K Hold
215
﹤0.01% 1233
2024
Q3
$2K Buy
215
+200
+1,333% +$1.73K ﹤0.01% 1234
2024
Q2
$0 Sell
15
-200
-93% -$1.8K ﹤0.01% 1367
2024
Q1
$2K Hold
215
﹤0.01% 1277
2023
Q4
$2K Hold
215
﹤0.01% 1282
2023
Q3
$2K Hold
215
﹤0.01% 1228
2023
Q2
$2K Hold
215
﹤0.01% 1248
2023
Q1
$2K Hold
215
﹤0.01% 1227
2022
Q4
$2K Hold
215
﹤0.01% 1241
2022
Q3
$2K Hold
215
﹤0.01% 1249
2022
Q2
$2K Hold
215
﹤0.01% 1256
2022
Q1
$2K Hold
215
﹤0.01% 1272
2021
Q4
$2K Buy
215
+95
+79% +$828 ﹤0.01% 1300
2021
Q3
$1K Hold
120
﹤0.01% 1285
2021
Q2
$2K Hold
120
﹤0.01% 1160
2021
Q1
$2K Hold
120
﹤0.01% 1164
2020
Q4
$2K Sell
120
-228
-66% -$4.09K ﹤0.01% 1141
2020
Q3
$5K Hold
348
﹤0.01% 1096
2020
Q2
$32K Hold
348
﹤0.01% 978
2020
Q1
$8K Buy
348
+28
+9% +$701 ﹤0.01% 1076
2019
Q4
$7K Sell
320
-33
-9% -$641 ﹤0.01% 1089
2019
Q3
$7K Hold
353
﹤0.01% 1056
2019
Q2
$6K Hold
353
﹤0.01% 1084
2019
Q1
$8K Buy
+353
New +$8.95K ﹤0.01% 1046
2018
Q4
Sell
-299
Closed -$10K 1184
2018
Q3
$10K Hold
299
﹤0.01% 1038
2018
Q2
$7K Hold
299
﹤0.01% 1075
2018
Q1
$7K Buy
+299
New +$8.21K ﹤0.01% 1058

Other funds holding TBPH

Daiwa Securities Group's TBPH Position: Q1 2026 in Review

Daiwa Securities Group sold out of Theravance Biopharma (TBPH) in Q1 2026, closing a stake of 115 shares — an estimated $2K sold.

Daiwa Securities Group first reported a position in TBPH in Q1 2018 and held it in 31 quarters. The position peaked at $32K in Q2 2020. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Daiwa Securities Group reported no remaining Theravance Biopharma position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 115 Theravance Biopharma shares in Q1 2026, an estimated $2K.
  • Daiwa Securities Group first reported a position in Theravance Biopharma in Q1 2018 and held it in 31 quarters.
  • Daiwa Securities Group's Theravance Biopharma position peaked at $32K in Q2 2020.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.